Palisade Bio (NASDAQ:PALI) Announces Quarterly Earnings Results

Palisade Bio (NASDAQ:PALI – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01), FiscalAI reports.

Palisade Bio Trading Up 3.5%

Shares of Palisade Bio stock opened at $1.17 on Thursday. Palisade Bio has a 12-month low of $1.08 and a 12-month high of $2.85. The firm has a market capitalization of $203.90 million, a price-to-earnings ratio of -2.44 and a beta of 1.61. The firm’s 50 day simple moving average is $1.52 and its two-hundred day simple moving average is $1.82.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PALI shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Monday, October 12th. HC Wainwright dropped their target price on Palisade Bio to $5.00 and set a “buy” rating on the stock in a research note on Wednesday. Wall Street Zen downgraded Palisade Bio from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Raymond James Financial began coverage on Palisade Bio in a research report on Thursday, October 8th. They set an “outperform” rating and a $6.00 target price on the stock. Finally, Oppenheimer reiterated an “outperform” rating on shares of Palisade Bio in a research note on Wednesday, October 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $9.00.

Read Our Latest Analysis on Palisade Bio

About Palisade Bio

(Get Free Report)

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Further Reading

Earnings History for Palisade Bio (NASDAQ:PALI)

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.